| Lessons in PROTAC design from selective degradation with a promiscuous warhead DP Bondeson, BE Smith, GM Burslem, AD Buhimschi, J Hines, ... Cell chemical biology 25 (1), 78-87. e5, 2018 | 811 | 2018 |
| The advantages of targeted protein degradation over inhibition: an RTK case study GM Burslem, BE Smith, AC Lai, S Jaime-Figueroa, DC McQuaid, ... Cell chemical biology 25 (1), 67-77. e3, 2018 | 624 | 2018 |
| Differential PROTAC substrate specificity dictated by orientation of recruited E3 ligase BE Smith, SL Wang, S Jaime-Figueroa, A Harbin, J Wang, BD Hamman, ... Nature communications 10 (1), 131, 2019 | 470 | 2019 |
| Activation of tumor suppressor protein PP2A inhibits KRAS-driven tumor growth J Sangodkar, A Perl, R Tohme, J Kiselar, DB Kastrinsky, N Zaware, ... The Journal of clinical investigation 127 (6), 2081-2090, 2017 | 203 | 2017 |
| Antigen identification and high-throughput interaction mapping by reprogramming viral entry CS Dobson, AN Reich, S Gaglione, BE Smith, EJ Kim, J Dong, L Ronsard, ... Nature methods 19 (4), 449-460, 2022 | 78 | 2022 |
| A biomaterial platform for T cell-specific gene delivery S Pandit, BE Smith, ME Birnbaum, Y Brudno Acta Biomaterialia 177, 157-164, 2024 | 3 | 2024 |
| Peptide-MHC-targeted retroviruses enable in vivo expansion and gene delivery to tumor-specific T cells EJK Xu, BE Smith, WD Conce Alberto, MJ Walsh, B Lim, MT Hoffman, ... bioRxiv, 2024.09. 18.613594, 2024 | 2 | 2024 |
| An In Vitro Pull-down Assay of the E3 Ligase: PROTAC: Substrate Ternary Complex to Identify Effective PROTACs DP Bondeson, BE Smith, AD Buhimschi Targeted Protein Degradation: Methods and Protocols, 135-150, 2021 | 2 | 2021 |
| Abstract C020: Identification of KRAS-specific TCRs from human peripheral blood J Shen, BE Smith, WC Alberto, EJ Kim, ML Dougan, H Singh, ... Cancer Research 84 (17_Supplement_2), C020-C020, 2024 | | 2024 |
| Library-based single-cell analysis of CAR signaling reveals drivers of in vivo persistence CR Perez, A Garmilla, A Nilsson, HM Baghdassarian, KS Gordon, ... bioRxiv, 2024.04. 29.591541, 2024 | | 2024 |
| Re-centauring T cell antigen discovery around CD4+ T cells BE Smith, AO Chan, ME Birnbaum Cell Reports Methods 4 (1), 2024 | | 2024 |
| 1232 Engineering a pseudotyped lentiviral platform to enable lineage-specific transduction of immune cells B Smith, S Dougan, M Birnbaum Journal for ImmunoTherapy of Cancer 10 (Suppl 2), 2022 | | 2022 |
| Abstract A218: Simultaneous inhibition of both the PI3K-AKT and MAPK-ERK pathways using a single small molecule based approach for the treatment of advanced cancer. N Dhawan, B Smith, J Sangodkar, V Gidwani, D Kastrinsky, M Ohlmeyer, ... Molecular Cancer Therapeutics 10 (11_Supplement), A218-A218, 2011 | | 2011 |
